EQS-News: CureVac Announces Voting Results of General Meeting (deutsch)

CureVac Announces Voting Results of General Meeting

Emittent / Herausgeber: CureVac / Schlagwort(e): Hauptversammlung

CureVac Announces Voting Results of General Meeting

24.06.2024 / 22:05 CET/CEST

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

CureVac Announces Voting Results of General Meeting

TÜBINGEN, Germany/BOSTON, USA - June 24, 2024 - CureVac N.V. (Nasdaq: CVAC),

a global clinical-stage biopharmaceutical company developing a new class of

transformative medicines based on messenger ribonucleic acid ("mRNA"), today

announced the voting results of the Company's annual general meeting.

The shareholders of the Company voted in favor of all proposals. These

proposals included the appointment of Thaminda Ramanayake and the

reappointment of Malte Greune as members of the Management Board, both

effective June 24th, 2024. Additionally, Jean Stéphenne and Mathias Hothum

were reappointed as members of the supervisory board, Birgit Hofmann was

appointed as a new member of the Supervisory Board effective June 24th,

2024, and KPMG Accountants N.V. was reappointed as the external auditors for

the financial year 2024.

A table containing tabulations of the votes casted is expected to be

released in the coming days.

About CureVac

CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of

messenger RNA (mRNA) technology, with more than 20 years of expertise in

developing, optimizing, and manufacturing this versatile biological molecule

for medical purposes. The principle of CureVac's proprietary technology is

the use of optimized mRNA as a data carrier to instruct the human body to

produce its own proteins capable of fighting a broad range of diseases. In

July 2020, CureVac entered in a collaboration with GSK to jointly develop

new products in prophylactic vaccines for infectious diseases based on

CureVac's second-generation mRNA technology. This collaboration was later

extended to the development of second-generation COVID-19 vaccine

candidates, and modified mRNA vaccine technologies. Based on its proprietary

technology, CureVac has built a deep clinical pipeline across the areas of

prophylactic vaccines, cancer therapies, antibody therapies, and the

treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen,

Germany, and has more than 1,100 employees across its sites in Germany, the

Netherlands, Belgium, Switzerland, and the U.S. Further information can be

found at www.curevac.com.

CureVac Media Contact

Patrick Perez, Junior Manager Public Relations

CureVac, Tübingen, Germany

T: +49 7071 9883-1831

patrick.perez@curevac.com

CureVac Investor Relations Contact

Dr. Sarah Fakih, Vice President Corporate Communications and Investor

Relations

CureVac, Tübingen, Germany

T: +49 7071 9883-1298

M: +49 160 90 496949

sarah.fakih@curevac.com

Forward-Looking Statements CureVac

This press release contains statements that constitute "forward looking

statements" as that term is defined in the United States Private Securities

Litigation Reform Act of 1995, including statements that express the

opinions, expectations, beliefs, plans, objectives, assumptions or

projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE,

CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac

Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and

CureVac Netherlands B.V. (the "company") regarding future events or future

results, in contrast with statements that reflect historical facts. Examples

include discussion of the potential efficacy of the company's vaccine and

treatment candidates and the company's strategies, financing plans, cash

runway, growth opportunities and market growth. In some cases, you can

identify such forward-looking statements by terminology such as

"anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or

"expect," "may," "will," "would," "could," "potential," "intend," or

"should," the negative of these terms or similar expressions.

Forward-looking statements are based on management's current beliefs and

assumptions and on information currently available to the company. However,

these forward-looking statements are not a guarantee of the company's

performance, and you should not place undue reliance on such statements.

Forward-looking statements are subject to many risks, uncertainties and

other variable circumstances, including negative worldwide economic

conditions and ongoing instability and volatility in the worldwide financial

markets, ability to obtain funding, ability to conduct current and future

preclinical studies and clinical trials, the timing, expense and uncertainty

of regulatory approval, reliance on third parties and collaboration

partners, ability to commercialize products, ability to manufacture any

products, possible changes in current and proposed legislation, regulations

and governmental policies, pressures from increasing competition and

consolidation in the company's industry, the effects of the COVID-19

pandemic on the company's business and results of operations, ability to

manage growth, reliance on key personnel, reliance on intellectual property

protection, ability to provide for patient safety, fluctuations of operating

results due to the effect of exchange rates, delays in litigation

proceedings, different judicial outcomes or other factors. Such risks and

uncertainties may cause the statements to be inaccurate and readers are

cautioned not to place undue reliance on such statements. Many of these

risks are outside of the company's control and could cause its actual

results to differ materially from those it thought would occur. The

forward-looking statements included in this press release are made only as

of the date hereof. The company does not undertake, and specifically

declines, any obligation to update any such statements or to publicly

announce the results of any revisions to any such statements to reflect

future events or developments, except as required by law.

For further information, please reference the company's reports and

documents filed with the U.S. Securities and Exchange Commission (SEC). You

may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Veröffentlichung einer Mitteilung, übermittelt durch EQS Group AG.

Medienarchiv unter https://www.eqs-news.com.

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

Sprache: Deutsch

Unternehmen: CureVac

Friedrich-Miescher-Str. 15

72076 Tübingen

Deutschland

EQS News ID: 1931849

Ende der Mitteilung EQS News-Service

 ISIN  NL0015436031

AXC0265 2024-06-24/22:05

Relevante Links: Curevac N.V.